Effect of Danazol on Solubilization of Immune Deposits in Patients With IgA Nephropathy

Yasuhiko Tomino, Hideto Sakai, Masahiko Miura, Takao Suga, Masayuki Endoh, Yasuo Nomoto
In: American Journal of Kidney Diseases · 1984 · vol. 4(2) , pp. 135–140 · doi:10.1016/s0272-6386(84)80061-x · PMID:6383029 · W2015528306
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This study investigated the impact of danazol on solubilizing immune deposits in IgA nephropathy patients, aiming to understand its potential therapeutic mechanism.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A study on the solubilization of glomerular immune deposits by administration of danazol in patients with IgA nephropathy is described. A clinical trial on danazol was performed in seven patient with IgA nephropathy. Administration of danazol was effective in improving proteinuria in patients with IgA nephropathy. In vitro effects of patients' sera on solubilization of glomerular immune deposits were examined in parallel studies. Renal biopsy specimens obtained from IgA nephropathy were incubated with fresh patients' sera before and after administration of danazol at 37 degrees C for one hour in plastic test tubes. The sections were stained with FITC-labeled heavy chain-specific anti-human IgA antiserum and then examined with a fluorescent microscope. It was shown that the solubilization of glomerular immune deposits by sera after administration of danazol from patients with IgA nephropathy was significantly higher than that by sera before such treatment.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

References (16)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-10T10:23:22.984393+00:00
unpaywall
last seen: 2026-09-03T06:36:50.994332+00:00
License: CC0 · commercial use OK